Abstract
Alzheimers disease (AD) is a progressive age-related neurodegenerative disorder with distinct neuropathological features. Extracellular plaques, consisting of aggregated amyloid peptides of 39-43 amino acids are one of the most prominent pathological hallmarks of this disease. Although the exact neurochemical effector mechanism of Aβ aggregation is not yet elucidated, age-associated disturbances of metal ion metabolism have been proposed to promote the formation of aggregates from soluble Aβ. Oxidative stress is postulated to be a downstream effect of Aβ-metal ion interactions. Therefore, the modulation of brain metal metabolism and attenuation of oxidative stress by antioxidant molecules are proposed as a potential therapeutic intervention in AD. Here, we summarize the recent literature focused on APP/Aβ-metal ion interactions and the use of antioxidant metal chelators as potential therapy against AD.
Keywords: Amyloid beta, Alzheimer, ’, s disease, oxidative stress and ion chelators
Current Pharmaceutical Design
Title: Antioxidants as a Potential Therapy Against Age-Related Neurodegenerative Diseases: Amyloid Beta Toxicity and Alzheimers Disease
Volume: 12 Issue: 6
Author(s): P. Hajieva and C. Behl
Affiliation:
Keywords: Amyloid beta, Alzheimer, ’, s disease, oxidative stress and ion chelators
Abstract: Alzheimers disease (AD) is a progressive age-related neurodegenerative disorder with distinct neuropathological features. Extracellular plaques, consisting of aggregated amyloid peptides of 39-43 amino acids are one of the most prominent pathological hallmarks of this disease. Although the exact neurochemical effector mechanism of Aβ aggregation is not yet elucidated, age-associated disturbances of metal ion metabolism have been proposed to promote the formation of aggregates from soluble Aβ. Oxidative stress is postulated to be a downstream effect of Aβ-metal ion interactions. Therefore, the modulation of brain metal metabolism and attenuation of oxidative stress by antioxidant molecules are proposed as a potential therapeutic intervention in AD. Here, we summarize the recent literature focused on APP/Aβ-metal ion interactions and the use of antioxidant metal chelators as potential therapy against AD.
Export Options
About this article
Cite this article as:
Hajieva P. and Behl C., Antioxidants as a Potential Therapy Against Age-Related Neurodegenerative Diseases: Amyloid Beta Toxicity and Alzheimers Disease, Current Pharmaceutical Design 2006; 12 (6) . https://dx.doi.org/10.2174/138161206775474297
DOI https://dx.doi.org/10.2174/138161206775474297 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells in Pharmaceutical Biotechnology
Current Pharmaceutical Biotechnology Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology
Current Alzheimer Research Why Fish and Fruit are Better than Fish and Chips in the Aging Process
Current Nutrition & Food Science Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets Role of Metals in Neuronal Apoptosis: Challenges Associated with Neurodegeneration
Current Alzheimer Research Role and Treatment of Mitochondrial DNA-Related Mitochondrial Dysfunction in Sporadic Neurodegenerative Diseases
Current Pharmaceutical Design Translational Imaging of Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Protein Cysteine Modifications: (1) Medicinal Chemistry for Proteomics
Current Medicinal Chemistry Editorial: [Hot Topic: Central Nervous System Drugs in the Treatment of Neurological Disorders]
Central Nervous System Agents in Medicinal Chemistry Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis
Current Stem Cell Research & Therapy Emerging Therapeutic Approaches Based on Nanotechnology for the Treatment of Diseases Associated with Telomere Dysfunction
Mini-Reviews in Medicinal Chemistry Development of Metabotropic Glutamate Receptor Ligands for Neuroimaging
Current Medical Imaging Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases
Current Topics in Medicinal Chemistry The Metabotropic Glutamate Receptor System: G-Protein Mediated Pathways that Modulate Neuronal and Vascular Cellular Injury
Current Medicinal Chemistry - Central Nervous System Agents Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Cannabinoid Drugs and Enhancement of Endocannabinoid Responses: Strategies for a Wide Array of Disease States
Current Molecular Medicine Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
Current Neuropharmacology Low Density Lipoprotein Receptor-Related Proteins (LRPs), Alzheimers and Cognition
Current Drug Targets - CNS & Neurological Disorders